PALI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of -49.65%. Palisade Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1294.52%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Palisade Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palisade Bio is more attractive than NovaBay Pharmaceuticals.

Palisade Bio has a beta of 1.464, which suggesting that the stock is 46.432% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Palisade Bio's net income of -$3.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Palisade Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of -- compared to Palisade Bio's net margin of --. Palisade Bio's return on equity of -- beat Internet Patents Corporation's return on equity of --.

Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1294.52%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Palisade Bio has higher upside potential than Internet Patents Corporation, analysts believe Palisade Bio is more attractive than Internet Patents Corporation.

Palisade Bio has a beta of 1.464, which suggesting that the stock is 46.432% more volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Internet Patents Corporation quarterly revenues of --. Palisade Bio's net income of -$3.3M is higher than Internet Patents Corporation's net income of --. Notably, Palisade Bio's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of 26.7%. Palisade Bio's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1294.52%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 46.1%. Given that Palisade Bio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Palisade Bio is more attractive than Regeneron Pharmaceuticals.

Palisade Bio has a beta of 1.464, which suggesting that the stock is 46.432% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Palisade Bio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Palisade Bio's net income of -$3.3M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Palisade Bio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -- compared to Palisade Bio's net margin of -489.18%. Palisade Bio's return on equity of -- beat Sutro Biopharma's return on equity of -204.67%.

Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1294.52%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 257.78%. Given that Palisade Bio has higher upside potential than Sutro Biopharma, analysts believe Palisade Bio is more attractive than Sutro Biopharma.

Palisade Bio has a beta of 1.464, which suggesting that the stock is 46.432% more volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.488%.

Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Palisade Bio quarterly revenues are --, which are smaller than Sutro Biopharma quarterly revenues of $14.8M. Palisade Bio's net income of -$3.3M is higher than Sutro Biopharma's net income of -$72.4M. Notably, Palisade Bio's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 1.19x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.